SEARCH

SEARCH BY CITATION

References

  • Anczukow O, Buisson M, Salles MJ, Triboulet S, Longy M, Lidereau R, Sinilnikova OM, Mazoyer S. 2008. Unclassified variants identified in BRCA1 exon 11: consequences on splicing. Genes Chromosomes Cancer 47:418426.
  • Andreutti-Zaugg C, Scott RJ, Iggo R. 1997. Inhibition of nonsense-mediated messenger RNA decay in clinical samples facilitates detection of human MSH2 mutations with an in vivo fusion protein assay and conventional techniques. Cancer Res 57:32883293.
  • Ars E, Serra E, de la Luna S, Estivill X, Lazaro C. 2000. Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA. Nucleic Acids Res 28:13071312.
  • Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, Chevrier A, Dugast C, Layet V, Rossi A, Lidereau R, Frebourg T, Hardouin A, Tosi M. 2008. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45:438446.
  • Brezin AP, Nedelec B, Barjol A, Rothschild PR, Delpech M, Valleix S. A new VCAN/versican splice acceptor site mutation in a French Wagner family associated with vascular and inflammatory ocular features. Mol Vis 17:16691678.
  • Cartegni L, Chew SL, Krainer AR. 2002. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285298.
  • Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. 2003. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:35683571.
  • Caux-Moncoutier V, Castera L, Tirapo C, Michaux D, Remon MA, Lauge A, Rouleau E, De Pauw A, Buecher B, Gauthier-Villars M, Viovy JL, Stoppa-Lyonnet D, Houdayer C. 2011. EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: Application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat 32:325334.
  • Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Castera L, De Pauw A, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Houdayer C. 2009. Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 17:14711480.
  • Corvelo A, Hallegger M, Smith CW, Eyras E. 2010. Genome-wide association between branch point properties and alternative splicing. PLoS Comput Biol 6:e1001016.
  • Dehainault C, Michaux D, Pages-Berhouet S, Caux-Moncoutier V, Doz F, Desjardins L, Couturier J, Parent P, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C. 2007. A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation. Eur J Hum Genet 15:473477.
  • Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. 2009. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67.
  • Doktor TK, Schroeder LD, Vested A, Palmfeldt J, Andersen HS, Gregersen N, Andresen BS. 2011. SMN2 exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3′ splice site. Hum Mutat 32:220230.
  • Fairbrother WG, Yeh RF, Sharp PA, Burge CB. 2002. Predictive identification of exonic splicing enhancers in human genes. Science 297:10071013.
  • Gaildrat P, Killian A, Martins A, Tournier I, Frebourg T, Tosi M. 2011. Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants. Methods Mol Biol 653:249257.
  • Hinzpeter A, Aissat A, Sondo E, Costa C, Arous N, Gameiro C, Martin N, Tarze A, Weiss L, de Becdelievre A, Costes B, Goossens M, Galietta LJ, Girodon E, Fanen P. 2011. Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier. PLoS Genet 6:e1001153.
  • Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FB. 2008. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat 29:12921303.
  • Holla OL, Nakken S, Mattingsdal M, Ranheim T, Berge KE, Defesche JC, Leren TP. 2009. Effects of intronic mutations in the LDLR gene on pre-mRNA splicing: comparison of wet-lab and bioinformatics analyses. Mol Genet Metab 96:245252.
  • Houdayer C, Dehainault C, Mattler C, Michaux D, Caux-Moncoutier V, Pages-Berhouet S, d'Enghien CD, Lauge A, Castera L, Gauthier-Villars M, Stoppa-Lyonnet D. 2008. Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat 29:975982.
  • Khan AO, Shinwari J, Al-Sharif L, Khalil DS, Al Tassan N. Prolonged pursuit by optokinetic drum testing in asymptomatic female carriers of novel FRMD7 splice mutation c.1050 +5 G>A. Arch Ophthalmol 129:936940.
  • Lastella P, Surdo NC, Resta N, Guanti G, Stella A. 2006. In silico and in vivo splicing analysis of MLH1 and MSH2 missense mutations shows exon- and tissue-specific effects. BMC Genomics 7:243.
  • Mahe P, Vert JP. 2009. Virtual screening with support vector machines and structure kernels. Comb Chem High Throughput Screen 12:409423.
  • Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C. 2010. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 120:391399.
  • Nalla VK, Rogan PK. 2005. Automated splicing mutation analysis by information theory. Hum Mutat 25:334342.
  • Orban TI, Olah E. 2003. Emerging roles of BRCA1 alternative splicing. Mol Pathol 56191197.
  • Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV. 2008. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:12821291.
  • Reese MG, Eeckman FH, Kulp D, Haussler D. 1997. Improved splice site detection in Genie. J Comput Biol 4:31123.
  • Shapiro MB, Senapathy P. 1987. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15:71557174.
  • Spurdle AB, Couch FJ, Hogervorst FB, Radice P, Sinilnikova OM. 2008. Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat 29:13041313.
  • Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. 2003. Random forest: a classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci 43:19471958.
  • Thery JC, Krieger S, Gaildrat P, Revillion F, Buisine MP, Killian A, Duponchel C, Rousselin A, Vaur D, Peyrat JP, Berthet P, Frebourg T, Martins A, Hardouin A, Tosi M. 2011. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet 19:10521058.
  • Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, Gutierrez-Enriquez S, Menendez M, Fachal L, Santamarina M, Steffensen AY, Jonson L, Agata S, et al. 2012. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat 132:10091023.
  • Tone Y, Toma T, Toga A, Sakakibara Y, Wada T, Yabe M, Kusafuka H, Yachie A. 2012. Enhanced exon 2 skipping caused by c.910G>A variant and alternative splicing of MEFV genes in two independent cases of familial Mediterranean fever. Mod Rheumatol 22:4551.
  • Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, Wang Q, Buisine MP, Soret J, Tazi J, Frebourg T, Tosi M. 2008. A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects. Hum Mutat 29:14121424.
  • Vreeswijk MP, Kraan JN, van der Klift HM, Vink GR, Cornelisse CJ, Wijnen JT, Bakker E, van Asperen CJ, Devilee P. 2009. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat 30:107114.
  • Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, Eccles DM, Lin F, Butler SA, Goff SA, Thompson BA, Lakhani SR, Da Silva LM, et al. 2011. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 31:E1484E1505.
  • Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM, Investigators K, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB. 2011. Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat 32:678687.
  • Wimmer K, Eckart M, Rehder H, Fonatsch C. 2000. Illegitimate splicing of the NF1 gene in healthy individuals mimics mutation-induced splicing alterations in NF1 patients. Hum Genet 106:311313.
  • Wimmer K, Roca X, Beiglbock H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L. 2007. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Hum Mutat 28:599612.
  • Yeo G, Burge CB. 2004. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377394.
  • Zhang C, Li WH, Krainer AR, Zhang MQ. 2008. RNA landscape of evolution for optimal exon and intron discrimination. Proc Natl Acad Sci U S A 105:5797802.
  • Zweig MH, Campbell G. 1993. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561577.